AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3115081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligosaccharides infusion
Number of subjects: 14
Study 30417279 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (n = 20)
Number of subjects: 30
Study 30417279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 27846922 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (2 mg, 4 mg) in short-term fixed-dose studies
Number of subjects: 0
Study 27846922 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (2-4 mg) in flexible-dose short-term study
Number of subjects: 0
Study 27846922 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole in maintenance study (1-4 mg)
Number of subjects: 0
Study 27846922 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole in all studies
Number of subjects: 0
Study 27846922 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole in short-term studies
Number of subjects: 0
Study 27846922 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole overall
Number of subjects: 0
Study 25829142 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg daily)
Number of subjects: 19
Study 25829142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23837527 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (handwritten messages and seasonal reports sent once a month for eight consecutive months)
Number of subjects: 180
Study 23837527 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention
Number of subjects: 180
Study 22104978 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions by a physical therapist and an empowerment trainer, and a Rest‐Break Tool
Number of subjects: 171
Study 20005355 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression regimen with 80% reduction of cyclosporine or tacrolimus (group 1)
Number of subjects: 20
Study 20005355 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression regimen with discontinuation of cyclosporine or tacrolimus (group 2)
Number of subjects: 20
Study 16430956 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-cured cement
Number of subjects: 0
Study 16430956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically cured cement
Number of subjects: 0
Study 16430956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured cements
Number of subjects: 0
Study 14704238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical placement of dinoprostone (n = 24)
Number of subjects: 63
Study 14704238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical placement of dinoprostone
Number of subjects: 63
Study 14704238 — intervention group
Group type: COMPARATOR
Intervention: Posterior fornix placement of dinoprostone (n = 22)
Number of subjects: 63
Study 11703236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (Harmonic scalpel)
Number of subjects: 32
Study 11703236 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 32
Study 9153737 — intervention group
Group type: EXPERIMENTAL
Intervention: N-9 vaginal gel (Advantage-24), 52.5 mg, applied once daily for 2 weeks
Number of subjects: 60
Study 9153737 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, applied once daily for 2 weeks
Number of subjects: 60
Study 8423760 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen (400 mg TID initiated 4 h before exercise)
Number of subjects: 20
Study 8423760 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ibuprofen (400 mg TID initiated 24 h after baseline)
Number of subjects: 20
Study 8423760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8423760 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 8423760 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 8423760 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 20
Study 8423760 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic and therapeutic ibuprofen
Number of subjects: 20
Study 3688278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 19
Study 3688278 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic withdrawal
Number of subjects: 19
Study 31595954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 53454
Study 31595954 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 53454
Study 31595954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) with prior AAD
Number of subjects: 53454
Study 28851132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (nursing assistant supervised home exercise programme)
Number of subjects: 148
Study 28851132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 148
Study 27213789 — intervention group
Group type: EXPERIMENTAL
Intervention: LAGB plus anterior fundoplication (group B)
Number of subjects: 40
Study 27213789 — intervention group
Group type: COMPARATOR
Intervention: LAGB alone (group A)
Number of subjects: 40
Study 27213789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24615684 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational/motivational intervention
Number of subjects: 62
Study 24615684 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical information (Control)
Number of subjects: 62
Study 22329591 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5 mg plus amiloride/hydrochlorothiazide 1.25-2.5 mg/12.5-25 mg (Group A)
Number of subjects: 13542
Study 22329591 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5 mg plus telmisartan 40-80 mg (Group T)
Number of subjects: 13542
Study 20520286 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg
Number of subjects: 511
Study 20520286 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 511
Study 20520286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 18772451 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 43
Study 18772451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18772451 — intervention group
Group type: COMPARATOR
Intervention: Control (nonwake-up group)
Number of subjects: 43
Study 15625265 — intervention group
Group type: EXPERIMENTAL
Intervention: BURP maneuver with cricoid pressure
Number of subjects: 43
Study 15625265 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure alone
Number of subjects: 43
Study 15625265 — intervention group
Group type: COMPARATOR
Intervention: No pressure
Number of subjects: 43
Study 12196749 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed twice daily
Number of subjects: 128
Study 12196749 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed once daily
Number of subjects: 128
Study 12196749 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed 5 times a week
Number of subjects: 128
Study 12196749 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed 3 times a week
Number of subjects: 128
Study 12196749 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 128
Study 10197891 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 44
Study 10197891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7760888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg per day for 48 hours)
Number of subjects: 9
Study 7760888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2328197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg 12 hourly
Number of subjects: 9
Study 2328197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg 12 hourly
Number of subjects: 9
Study 85937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg/day
Number of subjects: 16
Study 85937 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 16
Study 85937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg/day combined with propranolol 80 mg twice daily
Number of subjects: 16
Study 85937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31286480 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 205
Study 31286480 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 205
Study 31746775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygie (serious game)
Number of subjects: 269
Study 31746775 — intervention group
Group type: COMPARATOR
Intervention: Reading (traditional method)
Number of subjects: 269
Study 28889847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 28889847 — intervention group
Group type: COMPARATOR
Intervention: Sham-laser acupuncture
Number of subjects: 0
Study 28889847 — intervention group
Group type: COMPARATOR
Intervention: Medical symptom control
Number of subjects: 0
Study 26433717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.4% rice peptide CL(14-25)
Number of subjects: 10
Study 26433717 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 10
Study 23657005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transglucosidase (TGD) 300 or 900 mg/day for 12 weeks
Number of subjects: 60
Study 23657005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21851461 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressant
Number of subjects: 31
Study 19111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0
Study 19111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 0
Study 19111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 0
Study 19111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate
Number of subjects: 0
Study 19111223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17239888 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin/Niacin ER
Number of subjects: 292
Study 17239888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Niacin ER
Number of subjects: 292
Study 17239888 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Number of subjects: 292
Study 17239888 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 292
Study 15523985 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon CustomCornea
Number of subjects: 30
Study 15523985 — intervention group
Group type: COMPARATOR
Intervention: Bausch & Lomb Zyoptix
Number of subjects: 30
Study 11177313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and Methotrexate
Number of subjects: 42
Study 11177313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9428879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms/kg clonidine
Number of subjects: 20
Study 9428879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7699537 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization tracking system
Number of subjects: 597
Study 7699537 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 597
Study 2546778 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (etoposide, doxorubicin, methotrexate (VAM) and procarbacine, vincristine, cyclophosphamide, lomustine (POCC) with prophylactic cranial irradiation (30 Gy))
Number of subjects: 99
Study 2546778 — intervention group
Group type: COMPARATOR
Intervention: Sequential hemibody irradiation (SHBI)
Number of subjects: 99
Study 2546778 — intervention group
Group type: COMPARATOR
Intervention: Local and/or locoregional radiotherapy
Number of subjects: 99
Study 612628 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole, 50 mg/kg once
Number of subjects: 60
Study 612628 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole, 50 mg/kg once
Number of subjects: 60
Study 31747959 — intervention group
Group type: EXPERIMENTAL
Intervention: abPI‐VSD (antibiotic-containing drainage fluid)
Number of subjects: 75
Study 31747959 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic irrigation solution without abPI‐VSD
Number of subjects: 75
Study 28414548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen disgust condition
Number of subjects: 211
Study 28414548 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral disgust condition
Number of subjects: 211
Study 28414548 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 211
Study 28414548 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 2 (Independent sample of community adults, N = 121)
Number of subjects: 211
Study 27161750 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 27161750 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study 24356166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot spinal (SSS) technique
Number of subjects: 44
Study 24356166 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE) technique
Number of subjects: 44
Study 22567742 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin Sodium (LV/Na) with irinotecan or oxaliplatin combined with infusional 5-FU
Number of subjects: 57
Study 22567742 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin Calcium (LV/Ca) with irinotecan or oxaliplatin combined with infusional 5-FU
Number of subjects: 57
Study 20597110 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A)
Number of subjects: 190
Study 20597110 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (plus MTX)
Number of subjects: 190
Study 20597110 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 190
Study 20597110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus MTX)
Number of subjects: 190
Study 17600622 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 2 weeks
Number of subjects: 8
Study 17600622 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment scan
Number of subjects: 8
Study 15764868 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean achieved dose 106 +/- 38 mg/d)
Number of subjects: 31
Study 15764868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12589349 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 22
Study 12589349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10606310 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate with X-prep and clear liquid diet for 2 days (group A)
Number of subjects: 70
Study 10606310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulcolax for 2 days and Fleet enema without dietary restriction (group B)
Number of subjects: 70
Study 10606310 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely 20 ml/kg (up to 1 L) per hour for 4 h with clear liquid diet for 1 day (group C)
Number of subjects: 70
Study 8606813 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg/daily)
Number of subjects: 8
Study 8606813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2006519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 750 mg p.o. b.i.d.
Number of subjects: 26
Study 2006519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7152771 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight)
Number of subjects: 14
Study 7152771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6431741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye drops
Number of subjects: 60
Study 6431741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30654837 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary transvenous diaphragm pacing (TTVDP)
Number of subjects: 88
Study 30654837 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 88
Study 28532339 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐based physical activity intervention
Number of subjects: 55
Study 28532339 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 55
Study 26899019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 1209
Study 26899019 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 1209
Study 24971787 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 68
Study 24971787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 68
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 180 mg once daily for 4 weeks (study 1)
Number of subjects: 256
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg once daily for 8 weeks (study 2)
Number of subjects: 256
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg once daily for 8 weeks (study 2)
Number of subjects: 256
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 240 mg once daily for 8 weeks (study 2)
Number of subjects: 256
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg once daily
Number of subjects: 256
Study 22608107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (various doses)
Number of subjects: 256
Study 22608107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 20573633 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane-sufentanil (n = 51)
Number of subjects: 100
Study 20573633 — intervention group
Group type: COMPARATOR
Intervention: propofol-sufentanil (n = 49)
Number of subjects: 100
Study 18095196 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (5 mg/kg bolus and 500 mg/h for 24 hours)
Number of subjects: 70
Study 18095196 — intervention group
Group type: COMPARATOR
Intervention: Saline control (same volume as magnesium group)
Number of subjects: 70
Study 16098397 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant workload training (Group A)
Number of subjects: 42
Study 16098397 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive/increasing workload training (Group B)
Number of subjects: 42
Study 16098397 — intervention group
Group type: COMPARATOR
Intervention: No training (Group C)
Number of subjects: 42
Study 12552334 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF(k2*)
Number of subjects: 20
Study 12552334 — intervention group
Group type: EXPERIMENTAL
Intervention: rCBF(K1)
Number of subjects: 20
Study 12552334 — intervention group
Group type: EXPERIMENTAL
Intervention: PR(k2*)
Number of subjects: 20
Study 12552334 — intervention group
Group type: EXPERIMENTAL
Intervention: PR(K1)
Number of subjects: 20
Study 10655909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (kallikrein inhibitor)
Number of subjects: 0
Study 10655909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 10655909 — intervention group
Group type: COMPARATOR
Intervention: Propofol and its lipid solvent
Number of subjects: 0
Study 10655909 — intervention group
Group type: COMPARATOR
Intervention: Lipid solvent (injected before propofol)
Number of subjects: 0
Study 10655909 — intervention group
Group type: COMPARATOR
Intervention: Lipid solvent (injected twice)
Number of subjects: 0
Study 8909621 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for Peace intervention (comprehensive violence-prevention program)
Number of subjects: 8865
Study 8909621 — intervention group
Group type: COMPARATOR
Intervention: Control group (district's usual care of violence prevention activities)
Number of subjects: 8865
Study 1874199 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg kg‐1 (Group 1)
Number of subjects: 30
Study 1874199 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg kg‐1 (Group 2)
Number of subjects: 30
Study 6191948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 41
Study 6191948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate
Number of subjects: 41
Study 6191948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg methylphenidate)
Number of subjects: 41
Study 29570173 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental liquid diet
Number of subjects: 26
Study 29570173 — intervention group
Group type: COMPARATOR
Intervention: Commercial semisolid diet
Number of subjects: 26
Study 28079638 — intervention group
Group type: EXPERIMENTAL
Intervention: Preshaved axilla
Number of subjects: 20
Study 28079638 — intervention group
Group type: COMPARATOR
Intervention: Prewaxed axilla
Number of subjects: 20
Study 25376639 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 281
Study 25540089 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (MCI) consisting of a self-management/education program of six meetings, including e-Health interventions, followed for 12 months.
Number of subjects: 100
Study 25540089 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (MCI)
Number of subjects: 100
Study 25540089 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 100
Study 22806681 — intervention group
Group type: EXPERIMENTAL
Intervention: T12/PR48
Number of subjects: 662
Study 22806681 — intervention group
Group type: EXPERIMENTAL
Intervention: lead-in T12/PR48
Number of subjects: 662